Cargando…
Anti-IL17A Halts the Onset of Diabetic Retinopathy in Type I and II Diabetic Mice
There are ~463 million diabetics worldwide, and more than half have diabetic retinopathy. Yet, treatments are still lacking for non-proliferative diabetic retinopathy. We and others previously provided evidence that Interleukin-17A (IL-17A) plays a pivotal role in non-proliferative diabetic retinopa...
Autores principales: | Zhou, Amy Y., Taylor, Brooklyn E., Barber, Katherine G., Lee, Chieh A., Taylor, Zakary R. R., Howell, Scott J., Taylor, Patricia R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860974/ https://www.ncbi.nlm.nih.gov/pubmed/36674854 http://dx.doi.org/10.3390/ijms24021347 |
Ejemplares similares
-
Inhibition of CD40-TRAF6-dependent inflammatory activity halts the onset of diabetic retinopathy in streptozotocin-diabetic mice
por: Howell, Scott J., et al.
Publicado: (2022) -
RORγt Inhibitor-SR1001 Halts Retinal Inflammation, Capillary Degeneration, and the Progression of Diabetic Retinopathy
por: Zapadka, Thomas E., et al.
Publicado: (2020) -
IL-17A Enhances Retinal Neovascularization
por: Taylor, Brooklyn E., et al.
Publicado: (2023) -
Aryl Hydrocarbon Receptor Agonist VAF347 Impedes Retinal Pathogenesis in Diabetic Mice
por: Zapadka, Thomas E., et al.
Publicado: (2021) -
Retinal Inflammation, Oxidative Stress, and Vascular Impairment Is Ablated in Diabetic Mice Receiving XMD8-92 Treatment
por: Howell, Scott J., et al.
Publicado: (2021)